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Abstract
Background Angiotensin-converting enzyme (ACE) 2 is known to be a functional receptor for SARS-CoV-2 in the current 
pandemic. Soluble ACE2 (sACE2) concentrations are elevated in patients with various cardiovascular disorders including 
heart failure.
Methods In a total of 182 consecutive adult patients with complex congenital heart disease (CHD) and 63 healthy controls, 
sACE2 concentrations were measured in serum using the Human  ACE2® assay by Cloud-Clone Corporation and associated 
with clinical, laboratory and echocardiographic parameters.
Results Median sACE2 levels were increased in patients with complex CHD as compared to healthy controls (761.9 pg/ml 
vs 365.2 pg/ml, p < 0.001). Moreover, sACE2 concentrations were significantly elevated in patients with a higher NYHA 
class ≥ III (1856.2 pg/ml vs 714.5 pg/ml in patients with NYHA class I/II, p < 0.001). Using linear regression analysis, higher 
sACE2 levels were associated with a higher NYHA class ≥ III, more severe CHD, a morphological left systemic ventricle, 
higher creatinine and the use of mineralocorticoid receptor antagonists (MRA) in the univariable model. The use of ACE 
inhibitors or angiotensin receptor blockers (ARB) was associated with lower sACE2 levels. In the multivariable model, higher 
sACE2 levels were independently associated with a higher NYHA class ≥ III (p = 0.002) and lower sACE2 levels with the 
use of ACE inhibitors or ARB (p = 0.001).
Conclusion Soluble ACE2 concentrations were significantly increased in all types of complex CHD with highest levels 
found in patients with NYHA class ≥ III. Moreover, a higher NYHA class ≥ III was the most significant determinant that 
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Introduction
Angiotensin-converting enzyme 2 (ACE2) is a membrane-
bound carboxymonopeptidase that converts Angiotensin I 
and Angiotensin II into Angiotensin 1–9 and Angiotensin 
1–7, respectively, and is highly expressed on the surface of 
different organ cells in the heart, lungs, kidneys and testis 
[1–3]. The soluble form of ACE2 (by proteolytic shedding 
of membrane-bound ACE2) is also a key component of 
the counter-regulatory pathway within the renin–angioten-
sin–aldosterone system (RAAS) which plays a crucial role 
in the regulation of blood pressure, heart failure, diabetes 
and chronic kidney disease [4–6].
The current coronavirus SARS-CoV-2 uses ACE2 as a 
cellular receptor to invade target cells. In particular, the spike 
protein of SARS-CoV-2 is processed by transmembrane 
protease-serine 2 and favors the binding of the spike protein 
to ACE2 to enter the host cells [6]. To date, an increasing 
number of publications have confirmed the role of ACE2 
receptor for the cell entry mechanism of SARS-CoV-2 in the 
current pandemic [2, 3, 6]. Several epidemiological studies 
have also shown the severity of the SARS-CoV-2 disease 
(COVID-19) in older patients and particularly those with 
cardiovascular rather than pulmonary predisposing risk fac-
tors [7–9]. Thus, sACE2 concentrations were found to be 
elevated in men and older patients with different cardiovas-
cular morbidities, such as hypertension, diabetes, coronary 
heart disease and heart failure [8, 10–14]. These interactions 
of ACE2 may explain the higher vulnerability and predispo-
sition of such patients to have a severe or fatal outcome after 
SARS-CoV-2 infection [15–17].
Adult patients with complex congenital heart disease 
(CHD) may also represent a vulnerable group of patients 
due to comorbidities, residual heart defects with longstand-
ing pressure or volume overload as well as reduced intrin-
sic myocardial function finally resulting in symptomatic 
heart failure in early or mid-term adulthood [18]. Data on 
the SARS-CoV-2 infection rate in patients with CHD are 
still lacking. According to data from different countries and 
the Johns Hopkins University, children and young people 
seem to have a less severe time course and fatality rate with 
COVID-19 than older adults [19, 20] what may be due to 
lower sACE2 levels [21]. Moreover, an increased vulner-
ability of older and male patients with cardiovascular disease 
or heart failure can be seen that could also be related to 
increased sACE2 levels [10–12, 22]. In adult patients with 
complex CHD who often present with altered myocardial 
function or even symptomatic heart failure, data on sACE2 
levels are lacking. Thus, in the light of the dual role of ACE2 
during the current pandemic, the aim of our study was to 
assess sACE2 levels in this particular patient cohort and to 
evaluate determinants of sACE2 concentrations with special 




In our outpatient clinic for adults with CHD, several pro-
spective studies for the evaluation of different biomarkers 
in serum as well as micro-RNA signatures in whole blood 
had been performed in the past [23–25]. To assess sACE2 
concentrations, existing serum samples of these patients 
frozen at -80° C representing the pre-COVID-19 era were 
used for analysis. Thus, serum samples of 182 consecutive 
patients with complex CHD ≥ 18 years of age who were 
regularly seen in our outpatient clinic between 22/01/2015 
and 02/12/2019 were analyzed in the present study. Com-
plex CHD was classified according to current ACC/AHA 
guidelines [26] and mainly related to severe congenital heart 
defects including all forms of pulmonary atresia, cyanotic 
CHD, Eisenmenger syndrome, transposition of the great 
arteries (TGA), common arterial trunk, all kinds of sin-
gle ventricle physiology with or without Fontan palliation 
as well as CHD at increased risk for heart failure, such as 
tetralogy of Fallot [27]. Patients with mild or moderate 
CHD, pregnancy, severe renal dysfunction or dialysis and 
incapability to understand or sign informed consent were 
excluded. Of the 182 patients enrolled in the study, 60/182 
(33.0%) patients had corrective surgery of congenital right 
heart disease (CRHD), such as pulmonary atresia, tetralogy 
of Fallot or common arterial trunk, 62/182 (34.1%) patients 
had TGA of whom 40/62 (64.5%) patients had a systemic 
morphological right ventricle (TGA-RV) and 22/62 (35.5%) 
patients a systemic morphological left ventricle (TGA-LV) 
after arterial switch operation, 37/182 (20.3%) patients 
showed a single ventricle physiology after complete Fontan 
palliation (FONT) and in 23/182 (12.6%) patients a non-
corrected cyanotic heart defect or Eisenmenger syndrome 
classified as Eisenmenger physiology (EIS) was present. 
Mean age was 30.1 ± 10.5 years (range 18–62 years) and 
103 patients were male (56.6%). The study protocol has been 
described in detail previously [23]. 63 healthy subjects with 
a mean age of 31.6 ± 11.7 years (range 18–61 years) served 
as controls. The control group was mainly recruited within 
our institution and consisted of medical students, medical 
staff or family members. To rule out a hemodynamically 
relevant heart abnormality, a physical examination and 
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two-dimensional echocardiography were performed in all 
healthy participants. Clinical data of controls and patients 
are given in Table 1. All patients and healthy controls gave 
written informed consent before enrollment.
Data and biochemical analyses
Clinical data of the patients were collected from medical 
records. Echocardiographic data sets were analysed on an 
Echopac server (Echopac Version 6, GE Healthcare, Horten, 
Norway) and assessed by investigators blinded to the labora-
tory results.
Venous blood samples were drawn into standard sam-
pling tubes shortly after echocardiography, centrifuged at 
3000g and serum removed, allocated and frozen at − 80 °C 
before analysis of ACE2 levels. In the patient group, routine 
laboratory tests, such as liver function tests and creatinine 
measurements, were performed using standard laboratory 
techniques. NT-proBNP and high sensitive troponin T 
levels were measured using an electrochemiluminescence 
sandwich immunoassay  (Cobas® proBNP II and troponin 
T hs STAT, Roche Diagnostics, Basel, Switzerland) on the 
 Elecsys® 2010 analyzer. Levels of ACE2 were measured 
using a commercially available sandwich enzyme immuno-
assay (Human  ACE2®, Cloud-Clone Corporation, Houston, 
Texas, USA) on the  FLUOstar® Omega Microplate Reader 
(BMG LABTECH Inc., Cary, North Carolina, USA) and has 
been described in detail previously [28]. All biochemical 
analyses were performed by investigators blinded to the clin-
ical and echocardiographic data of the patients. Glomerular 
filtration rate (GFR) was estimated using the chronic kidney 
disease epidemiology collaboration (CKD-EPI) creatinine 
equation [29].
Statistical analysis
Data were analysed using standard statistical software (SPSS 
version 25; SPSS Inc., Chicago, Illinois). Continuous vari-
ables are expressed as mean ± standard deviation or median 
(interquartile interval) as appropriate. Differences between 
unpaired groups were analysed using a Mann–Whitney U 
or Kruskal–Wallis test for continuous variables and a chi-
square test for nominal variables. Linear regression analysis 
was used in a univariable and multivariable way to iden-
tify determinants of sACE2 levels. For regression analysis, 
sACE2 concentrations were  log10 transformed due to the 
skewed distribution. In the multivariable model, variables 
were entered that gave statistically significant values in the 
univariable model and did not show any multicollinearity. 
The multivariable model was based on forward stepwise 
regression. A two-tailed p value < 0.05 was considered sta-
tistically significant.
Results
Study population and sACE2 levels
Clinical characteristics of patients based on quartile serum 
sACE2 concentrations are shown in Table 2. In patients with 
complex CHD, sACE2 levels ranged from 55.0 to 4526.1 pg/
ml with a median of 761.9 pg/ml (419.2–1277.7 pg/ml) 
and were significantly elevated as compared to healthy 
controls showing a median sACE2 level of 365.2 pg/ml 
(237.7–656.3  pg/ml; p < 0.001). Significantly elevated 
sACE2 levels were found in all subgroups of CHD patients 
in comparison to the healthy control group with highest 
Table 1  Comparison of healthy 
controls and patients
Mean ± standard deviation or median (interquartile interval) are used
NYHA New York Heart Association, SV systemic ventricle, VTI velocity time integral, sACE2 soluble angi-
otensin-converting enzyme 2
* Mann–Whitney U test
Variables Healthy controls (n = 63) All patients (n = 182) p value*
Age at enrollment (years) 31.6 ± 11.7 30.1 ± 10.5 0.474
Male sex 39/63 (61.9%) 103/182 (56.6%) 0.462
Body mass index (kg/m2) 23.2 ± 3.3 23.9 ± 4.8 0.579
NYHA class 1.0 ± 0 1.5 ± 0.7 < 0.001
Systolic blood pressure (mmHg) 120.8 ± 10.9 123.3 ± 13.9 0.304
Diastolic blood pressure (mmHg) 70.2 ± 7.7 70.8 ± 9.4 0.829
Transcutaneous oxygen saturation at rest (%) 98.2 ± 1.2 95.0 ± 5.9 < 0.001
Ejection fraction of SV (%) 62.4 ± 4.4 54.9 ± 9.1 < 0.001
Enddiastolic volume of SV (ml) 107.9 ± 26.9 131.9 ± 62.2 0.006
Endsystolic volume of SV (ml) 40.5 ± 12.6 61.9 ± 37.7 < 0.001
VTI above aortic valve (cm) 27.4 ± 4.3 24.4 ± 4.5 < 0.001
sACE2 concentrations (pg/ml) 365.2 (237.7–656.3) 761.9 (419.2–1277.7) < 0.001
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levels seen in patients with Eisenmenger physiology (median 
1418.4 pg/ml) (Fig. 1). Moreover, patients with a systemic 
morphological left ventricle displayed higher sACE2 levels 
than those with a systemic morphological right ventricle 
(median 841.7 pg/ml vs 633.9 pg/ml, p = 0.026). Soluble 
ACE2 levels were also significantly increased in patients 
with a higher NYHA class ≥ III reflecting advanced heart 
failure as compared to patients with NYHA class I/II 
(median 1856.2 pg/ml vs 714.5 pg/ml, p < 0.001) (Fig. 2).
Association of sACE2 levels with different variables
Linear regression analysis revealed that higher sACE2 
levels were significantly correlated with a higher NYHA 
class ≥ III, the presence of Eisenmenger physiology repre-
senting more severe CHD, a left ventricular morphology of 
the systemic ventricle, higher creatinine levels as well as 
the use of mineralocorticoid receptor antagonists (MRA) in 
the univariable model (Table 3). In contrast, the use of ACE 
inhibitors (ACEI) or angiotensin receptor blockers (ARB) 
was associated with lower sACE2 levels. Interestingly, 
sACE2 concentrations were only weakly related to NT-
proBNP (r = 0.127, p = 0.024) or high sensitive troponin T 
levels (r = 0.274, p = 0.010) in our study cohort.
In the multivariable model, however, the most significant 
factor independently associated with higher levels of sACE2 
was found to be a higher NYHA class ≥ III (p = 0.002) 
whereas the use of ACEI or ARB was the most significant 
factor associated with lower levels of sACE2 (p = 0.001).
Discussion
In our study, significantly higher sACE2 serum levels were 
found in adult patients with complex CHD in comparison to 
healthy controls indicating the relationship of ACE2 expres-
sion to cardiovascular disease. Soluble ACE2 levels differed 
significantly between the studied CHD subgroups with high-
est concentrations found in the EIS subgroup, thus reflecting 
the severity of CHD (Fig. 1). Interestingly, patients with 
TGA-LV after the arterial switch procedure showed higher 
sACE2 levels than those with TGA-RV after the atrial switch 
Table 2  Baseline characteristics of patients according to sACE2 quartiles
Mean ± standard deviation or median (interquartile interval) are used
sACE2 soluble angiotensin-converting enzyme 2, NYHA New York Heart Association, SV systemic ventricle, VTI velocity time integral, GFR 
glomerular filtration rate, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, MRA mineralocorticoid receptor 
antagonists
* Kruskal–Wallis test











Age at enrollment (years) 30.4 ± 9.8 29.5 ± 10.1 29.2 ± 10.2 31.4 ± 12.0 0.757
Male sex 25/45 (55.6%) 25/46 (54.3%) 28/46 (60.9%) 25/45 (55.6%) 0.925
NYHA class 1.4 ± 0.5 1.4 ± 0.5 1.5 ± 0.7 1.8 ± 0.8 0.090
Systolic blood pressure (mmHg) 122.9 ± 12.0 125.1 ± 14.8 121.6 ± 13.9 123.6 ± 15.0 0.849
Diastolic blood pressure (mmHg) 69.6 ± 7.6 72.4 ± 9.8 69.7 ± 9.3 71.6 ± 10.7 0.489
Transcutaneous oxygen saturation 
at rest (%)
96.8 ± 2.8 96.3 ± 6.2 94.8 ± 5.8 92.2 ± 8.2 0.012
Presence of atrial fibrillation 0/45 (0%) 1/46 (2.2%) 2/46 (4.3%) 3/45 (6.7%) 0.326
Left ventricular morphology of SV 25/45 (55.6%) 31/46 (67.4%) 39/46 (84.8%) 33/45 (73.3%) 0.160
Ejection fraction of SV (%) 55.2 ± 8.5 56.5 ± 8.1 55.2 ± 9.4 53.0 ± 10.3 0.326
VTI above aortic valve (cm) 24.4 ± 3.9 25.8 ± 4.8 24.0 ± 4.7 23.6 ± 4.2 0.200
Creatinine (mg/dl) 0.81 (0.75–0.95) 0.85 (0.71–0.96) 0.85 (0.75–0.95) 0.94 (0.81–1.09) 0.013
Estimated GFR (ml/min) 106.9 (96.5–117.6) 109.5 (96.3–121.8) 109.5 (91.3–120.2) 99.6 (71.7–118.5) 0.313
NT-proBNP (ng/l) 151.0 (64.5–236.3) 206.4 (87.8–314.9) 125.5 (67.0–237.2) 255.3 (89.6–627.7) 0.022
High sensitive troponin T (pg/ml) 5.0 (3.0–6.0) 4.0 (3.0–8.0) 5.0 (3.0–7.0) 5.0 (3.0–13.5) 0.496
Medication
 ACEI or ARB 14/45 (31.1%) 8/46 (17.4%) 9/46 (19.6%) 5/45 (11.1%) 0.116
 β-blockers 13/45 (28.9%) 10/46 (21.7%) 15/46 (32.6%) 17/45 (37.8%) 0.402
 MRA 3/45 (6.7%) 7/46 (15.2%) 9/46 (19.6%) 11/45 (24.4%) 0.135
 Loop diuretics or thiazides 10/45 (22.2%) 9/46 (19.6%) 11/46 (23.9%) 18/45 (40.0%) 0.116
 Antiarrhythmics 2/45 (4.4%) 0/46 (0%) 3/46 (6.5%) 7/45 (15.6%) 0.072
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operation what may be due to the morphology of the sys-
temic ventricle since patients with a systemic morphological 
right ventricle showed lower sACE2 levels than those with 
a systemic morphological left ventricle. In addition, sACE2 
concentrations were significantly increased in patients with 
NYHA class ≥ III reflecting advanced heart failure (Fig. 2).
Soluble ACE2 levels in other patient cohorts
Our results are consistent with a previous study illustrat-
ing increasing plasma sACE2 concentrations according 
to NYHA class in heart failure patients with highest lev-
els found in the acute setting [30]. Moreover, in that study, 
sACE2 concentrations were found to be elevated in patients 
Fig. 1  Boxplots display-
ing sACE2 levels in healthy 
controls and patients with vari-
ous types of congenital heart 
defects. *p < 0.05, **p = 0.001, 
***p < 0.001 as compared 
to controls. CRHD corrected 
congenital right heart disease, 
TGA transposition of the great 
arteries, RV systemic right ven-
tricle, FONT Fontan palliation, 
LV systemic left ventricle, EIS 
Eisenmenger physiology
Fig. 2  Boxplots illustrating 
sACE2 levels in patients with 
NYHA class I/II compared to 
NYHA class ≥ III
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receiving MRA or loop diuretics whereas no difference was 
seen with the use of ACEI or ARB medication. Although 
brain natriuretic peptide levels were significantly related to 
sACE2 levels in that study, correlation of NT-proBNP with 
sACE2 was rather weak in our cohort of patients.
Elevated sACE2 levels were also detected in male and 
female patients with coronary heart disease using the same 
sACE2 assay by Cloud-Clone Corporation as in our study 
[31]. Surprisingly, the coronary heart disease patients 
displayed markedly higher sACE2 concentrations (about 
5000–6000 pg/ml) than our CHD patients with NYHA 
class ≥ III (approximately 2000 pg/ml). These differences 
may be due to the different cardiovascular comorbidities 
(e.g. higher prevalence of cardiovascular risk factors, such 
as arterial hypertension or diabetes) and the ischemic patho-
physiology of altered myocardial function in the cohort with 
coronary heart disease. Hence, sACE2 levels were also sig-
nificantly higher in patients with multi-vessel than single-
vessel disease in that study. In contrast, altered myocardial 
function in CHD patients is mainly due to longstanding pres-
sure or volume overload.
Determinants of sACE2 levels
In the linear regression analysis, increased sACE2 levels 
were significantly related to a higher NYHA class ≥ III, more 
severe CHD, left ventricular morphology of the systemic 
ventricle, higher creatinine values and the use of MRA in 
the univariable model (Table 2). However, multivariable 
analysis revealed that a higher NYHA class ≥ III was the 
most significant determinant that was independently asso-
ciated with higher sACE2 concentrations. In addition, the 
use of ACEI or ARB medication was independently associ-
ated with lower sACE2 concentrations. Our results are in 
accordance with a previous study investigating two inde-
pendent cohorts of patients with left heart failure illustrat-
ing that ACEI or  ARB uses were independent predictors of 
lower sACE2 concentrations whereas the use of MRA was 
an independent predictor of higher sACE2 concentrations 
[22]. In contrast to that study, however, sACE2 levels were 
not found to be higher in male or older patients in our study 
population what may be due to the different age of the stud-
ied patients. In our CHD cohort, patients were rather young 
with a mean age of about 30 years in contrast to the older 
age of the patients studied by Sama et al. with a median age 
of 70 years [22].
Study limitations
Our study had some limitations that need to be addressed. 
First, evaluation of the direct association of the measured 
sACE2 concentrations and the infection risk or severity of 
COVID-19 disease is currently not possible because data 
on the incidence of COVID-19 disease is not yet available 
for our study cohort. Moreover, sACE2 concentrations may 
not necessarily represent membrane-bound ACE2 expres-
sion because previous studies indicate that ACE2 shed-
ding is mediated by a disintegrin and metalloproteinase 
Table 3  Univariable and 
multivariable linear regression 
analysis for determinants of 
sACE2 levels
sACE2 soluble angiotensin-converting enzyme 2, NYHA New York Heart Association, EIS Eisenmenger 
physiology, ACEI ACE inhibitors, ARB angiotensin receptor blockers, MRA mineralocorticoid receptor 
antagonists
Univariable analysis Multivariable analysis
Regression 
coefficient
p value Regression coefficient (95% CI) p value
Age at enrollment − 0.001 0.835 – –
Male sex 0.018 0.756 – –
NYHA class ≥ III 0.414 < 0.001 0.324 (0.117–0.530) 0.002
Diagnosis of EIS 0.313 < 0.001 – –
Presence of atrial fibrillation 0.301 0.065 – –
Left ventricular morphology of SV 0.138 0.028 – –
Transcutaneous oxygen saturation at rest − 0.019 < 0.001 – –
Creatinine 0.436 0.001 0.274 (0.007–0.540) 0.044
Glomerular filtration rate − 0.003 0.027 – –
Medication
 ACEI or ARB − 0.202 0.006 − 0.221 (− 0.356–0.087) 0.001
 β-blockers 0.023 0.713 – –
 MRA 0.167 0.034 – –
 Loop diuretics or thiazides 0.121 0.067 – –
 Antiarrhythmics 0.219 0.053 – –
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(ADAM)-17 and may not be applied to the total extent of 
tissue-bound ACE2 activity [32–34]. Thus, the relation of 
sACE2 and the extent of ADAM-17 activity or membrane-
bound ACE2 shedding is still unclear. Nevertheless, in the 
clinical setting, male sex, older age, the presence of cardio-
vascular risk factors or heart failure are  known to be highly 
predictive for a severe course of COVID-19 disease [8, 16] 
and could be due to increased sACE2 concentrations [21, 
22, 35]. However, further studies are warranted to evaluate 
the direct relationship of sACE2 concentrations and the sus-
ceptibility or course of COVID-19 disease in adult patients 
with complex CHD.
Conclusion
Soluble ACE2 concentrations were significantly elevated 
in adults with various types of complex CHD as compared 
to healthy controls with highest levels found in those with 
Eisenmenger physiology or a higher NYHA-class ≥ III 
reflecting advanced heart failure. However, a higher NYHA 
class ≥ III was the most significant determinant that was 
independently associated with increased sACE2 levels.
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